Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Genus holds gloomy guidance as tough conditions persist

(Sharecast News) - There were few surprises in Genus's interim results on Thursday after a detailed trading update from the animal genetics company just last week, as it reported a 31% drop in adjusted profits as expected. Shares in Genus tanked 16% on 15 February after the company guided to full-year adjusted pre-tax profit of £58m, owing to challenging markets, well below the consensus forecast for a similar outcome from last year's £71.5m.

However, an absence of bad news its interim results has provided some reassurance, with shares rising 2.5% at 1,960p following the figures on Thursday morning.

In line with recent guidance, Genus said revenues were £334m in the six months to 31 December, down 5% on the previous year, which it described as "resilient" in a tough environment. At constant currency, revenues would have risen 1%.

Adjusted pre-tax profit was down 26% year-on-year on a reported basis at £29m due to weakness in China, particularly in its porcine business PIC and dairy/cattle unit ABS. In the latter specifically, demand for dairy genetics in China was hit by a double-digit decline in the dairy herd.

As mentioned last week, Genus is now undergoing a so-called "Value Acceleration Programme" in ABS to improve profitability and returns from investments.

"We have taken rapid action including initiating a comprehensive programme to accelerate the value delivery from our bovine operations," said chief executive Jorgen Kokke.

"We have also completed a strategic review of R&D activities. The company is benefitting from savings achieved in the first half and will benefit further in the second half of the year and into FY25, as we optimise resource allocation to best deliver our growth objectives."

The company said there was no change to the full-year guidance given last week, assuming that current market conditions persist for the rest of the year.

"We are seeing the positive impact of our actions to accelerate value delivery which will deliver further benefit in the second half and in subsequent years," Kokke said.

Share this article

Related Sharecast Articles

Cranswick buys JSR Genetics, hails 'strong' Q3 revenue growth
(Sharecast News) - Cranswick backed its full-year expectations on Tuesday as it reported strong third-quarter revenue growth and announced the acquisition of UK pig genetics business JSR Genetics.
Elementis FY profit seen ahead of market views after strong Q4
(Sharecast News) - Elementis said on Tuesday that full-year operating profit was set to be ahead of market expectations following a strong fourth-quarter performance.
Tritax Big Box acquires Heathrow data centre development site
(Sharecast News) - Tritax Big Box announced the £70m acquisition of a 74-acre site within the Slough Availability Zone at Heathrow on Tuesday, to develop a major data centre project with a total potential capacity of 147 megawatts.
OptiBiotix launches SlimBiome products on Amazon India
(Sharecast News) - OptiBiotix Health announced the launch of multiple SlimBiome-containing products under its GoFigure brand on Amazon India on Monday, marking a strategic expansion into the country's rapidly growing weight management market.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.